Overview
- The five-year co-investment establishes a South San Francisco site targeted to open by late March, with Nvidia engineers working alongside Lilly scientists.
- The lab will use NVIDIA’s BioNeMo platform and the next-generation Vera Rubin architecture, with wider Rubin system availability reported to arrive later in 2026.
- A central objective is generating high-quality “ground truth” datasets through automated wet labs to train foundation models and tighten the hypothesis-to-discovery cycle.
- The scope includes clinical development and manufacturing, using digital twins and robotics to improve production capacity and supply chain reliability.
- Some commercial details were not disclosed, and outcomes will depend on validation, regulatory scrutiny and execution, as Lilly also brings a Blackwell-based AI supercomputer online.